Seeking Alpha

Pharmacyclics (PCYC -0.6%) enrolls a fifth patient in a Phase III trial of its ibrutinib drug...

Pharmacyclics (PCYC -0.6%) enrolls a fifth patient in a Phase III trial of its ibrutinib drug for treating forms of leukemia or lymphoma and triggers a third $50M milestone payment from J&J (JNJ) unit Janssen Biotech. The company may receive up to an extra $675M in milestones, bringing total upfront and milestone payments to $975M. (PR)
Comments (1)
  • fred1724
    , contributor
    Comments (67) | Send Message
     
    It's a shame that castigating pharma companies for high prices never addresses the huge investment required to bring a drug to market.
    15 Oct 2012, 04:58 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector